See more : XORTX Therapeutics Inc. (XRTX.V) Income Statement Analysis – Financial Results
Complete financial analysis of CBD Life Sciences Inc. (CBDL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of CBD Life Sciences Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Paradigm Oil and Gas, Inc. (PDGO) Income Statement Analysis – Financial Results
- 1812 Brewing Company Inc. (KEGS) Income Statement Analysis – Financial Results
- Jacquet Metals SA (JCQ.PA) Income Statement Analysis – Financial Results
- IGO Limited (IGO.AX) Income Statement Analysis – Financial Results
- Pretium Resources Inc. (0VDK.L) Income Statement Analysis – Financial Results
CBD Life Sciences Inc. (CBDL)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://lbcbioscienceinc.com
About CBD Life Sciences Inc.
CBD Life Sciences Inc. engages in the development and marketing a line of cannabidiol based organic products. Its cannabidiol based organic products include hemp drops, massage oils, recovery pain relief creams, anxiety and sleep solutions supplements, edibles, and a line of pet products. The company is based in Scottsdale, Arizona.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 167.15K | 160.24K | 59.26K | 225.90K | 79.64K | 122.79K | 155.55K | 0.00 | 0.00 |
| Cost of Revenue | 197.75K | 440.50K | 207.51K | 438.13K | 43.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -30.60K | -280.26K | -148.25K | -212.23K | 36.63K | 122.79K | 155.55K | 0.00 | 0.00 |
| Gross Profit Ratio | -18.31% | -174.90% | -250.18% | -93.95% | 46.00% | 100.00% | 100.00% | 0.00% | 0.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 30.20K | 0.00 | 1.39K | 314.85 | 337.43 | 752.49K | 442.90K | 53.29K | 44.12K |
| Selling & Marketing | 11.34K | 0.00 | 4.41K | 30.00 | 111.54 | 108.00K | 17.48K | 6.46K | 8.02K |
| SG&A | 46.05K | 571.77K | 4.96M | 171.86K | 906.25K | 860.49K | 460.38K | 59.75K | 52.14K |
| Other Expenses | 0.00 | -7.78K | -17.86K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 47.97K | 579.55K | 4.98M | 171.86K | 906.25K | 883.80K | 499.04K | 155.72K | 52.74K |
| Cost & Expenses | 245.72K | 1.02M | 5.19M | 609.99K | 949.26K | 883.80K | 499.04K | 155.72K | 52.74K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 69.91K | 0.00 | 15.27K | 23.50K | 0.00 | 0.00 |
| Depreciation & Amortization | 55.56K | 53.56K | 236.56K | 206.30K | 171.86K | 23.31K | 38.66K | 95.97K | 0.00 |
| EBITDA | -23.02K | -806.25K | -5.13M | -1.31M | -869.62K | -741.56K | -304.97K | -60.36K | -52.74K |
| EBITDA Ratio | -13.77% | -503.14% | -8,654.23% | -170.03% | -1,092.01% | -600.79% | -195.96% | 0.00% | 0.00% |
| Operating Income | -78.57K | -859.80K | -5.13M | -384.09K | -869.62K | -780.14K | -367.14K | -156.33K | -52.74K |
| Operating Income Ratio | -47.01% | -536.57% | -8,654.23% | -170.03% | -1,092.01% | -635.35% | -236.02% | 0.00% | 0.00% |
| Total Other Income/Expenses | 0.00 | -4.00 | -2.00 | -1.31M | 8.61K | -15.27K | -23.50K | 0.00 | 0.00 |
| Income Before Tax | -78.57K | -859.80K | -5.13M | -1.69M | -861.01K | -780.14K | -367.14K | -156.33K | -52.74K |
| Income Before Tax Ratio | -47.01% | -536.57% | -8,654.24% | -750.07% | -1,081.20% | -635.35% | -236.02% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 4.00 | -6.14K | -384.09 | -75.24 | 15.27K | 23.50K | 610.00 | 0.00 |
| Net Income | -78.57K | -859.80K | -5.13M | -1.69M | -861.01K | -780.14K | -367.14K | -156.33K | -52.74K |
| Net Income Ratio | -47.01% | -536.57% | -8,654.24% | -750.07% | -1,081.20% | -635.35% | -236.02% | 0.00% | 0.00% |
| EPS | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 | -428.18 | -2.29K | -2.41K | -893.95 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 | -428.18 | -2.29K | -2.41K | -893.95 |
| Weighted Avg Shares Out | 40.71B | 40.71B | 12.30B | 934.78M | 108.36M | 1.82K | 160.00 | 65.00 | 59.00 |
| Weighted Avg Shares Out (Dil) | 40.71B | 40.71B | 12.30B | 934.78M | 108.36M | 1.82K | 160.00 | 65.00 | 59.00 |
CBD Life Sciences, Inc. (CBDL) Reports Stunning 622% Revenue Growth From June to November 2024
Exploding with momentum: CBDL shatters records with 622% revenue growth in five months, propelling to a 1,405% year-to-date increase-a game-changer in the CBD industry. SCOTTSDALE, ARIZONA / ACCESSWIRE / December 5, 2024 / CBD Life Sciences, Inc. (CBDL), a leading...
CBD Life Sciences Inc. (CBDL) Closes on LOI for Potential $8 Million Revenue Cannabis Dispensary
With the New York cannabis market projected to surpass $5 billion by 2027, this acquisition positions CBDL for exponential revenue growth and expanded market dominance. SCOTTSDALE, AZ / ACCESSWIRE / November 19, 2024 / CBD Life Sciences Inc. (OTC PINK:CBDL),...
CBD Life Sciences Inc. (CBDL) Applies for Beer & Liquor License to Sell CBD Wine
Company is creating its own wine. Capitalizing on the projected $2.1 billion U.S. CBD-infused beverage market by 2025, CBDL positions itself at the forefront of innovation, unlocking immense revenue potential in the booming CBD alcohol sector.
CBD Life Sciences, Inc. (CBDL) Positioned for Unmatched Growth as Trump Welcomes Weed Legalization and Federal Rescheduling
The global cannabis market size was valued at USD 43.72 billion in 2022 and is projected to grow from USD 57.18 billion in 2023 to USD 444.34 billion by 2030, exhibiting a CAGR of 34.03% during the forecast period. North...
CBD Life Sciences Inc. (CBDL) Announces Grand View Research Report Findings on High-Growth CBD Equine Market, Aiming to Drive Unprecedented Shareholder Value
The global CBD pet care market, which includes products for animals like dogs, cats, and horses, was valued at approximately $125 million in 2020 and is expected to grow at a compound annual growth rate (CAGR) of 40.3% from 2021...
CBD Life Sciences Inc. (CBDL) Positioned for Significant Growth Amid Nationwide Marijuana Legalization Push
With the potential for explosive profits in a $70 billion industry, CBDL's innovative product line and strategic market positioning stand ready to deliver unparalleled returns for shareholders, making this a true game changer in the Hemp market With the potential...
CBD Life Sciences Inc. (CBDL) Positioned for Significant Growth Amid Nationwide Marijuana Legalization Push
With the potential for explosive profits in a $70 billion industry, CBDL's innovative product line and strategic market positioning stand ready to deliver unparalleled returns for shareholders, making this a true game changer in the Hemp market. SCOTTSDALE, AZ /...
CBD Life Sciences, Inc. (CBDL) Announces a Staggering 1744.00% Revenue Growth as Innovation and Strategic Expansion Drive Market Dominance
As the global CBD market is projected to reach $47 billion by 2028, CBDL's groundbreaking product innovations, retail expansion, and strategic partnerships position the company for unparalleled growth and industry leadership. SCOTTSDALE, AZ / ACCESSWIRE / October 17, 2024 /...
CBD Life Sciences, Inc. (CBDL) Announces Strategic MOU With U.S. Armed Forces for Groundbreaking Mushroom Supplement
CBD Life Sciences propels its expansion with a major MOU, positioning the company for multi-million-dollar growth in the booming $14.6 billion adaptogens market. SCOTTSDALE, AZ / ACCESSWIRE / October 15, 2024 / CBD Life Sciences, Inc. (OTC PINK:CBDL) is excited...
CBD Life Sciences Inc. (CBDL) Targets Alibaba as the Next Retail Giant for Wholesale Expansion of Top-Selling CBD Products
Leveraging Alibaba's 1.28 billion annual active consumers and $3 trillion in gross merchandise volume to accelerate growth and global market penetration. SCOTTSDALE, AZ / ACCESSWIRE / October 10, 2024 / CBD Life Sciences Inc. (OTC PINK:CBDL), a trailblazer in the...
Source: https://incomestatements.info
Category: Stock Reports